A part of Watch Media

MedWatchWednesday1 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
14/12/2022at 14:33

New Danish government to extend a hand to life science companies

After historically lengthy negotiations, a new Danish government has presented an agenda including a plan to strengthen Denmark’s life science industry, which stars Novo Nordisk, Lundbeck, and Genmab.
Mette Frederiksen, prime minister of Denmark
by mikkel aabenhus hemmingsen, translated by daniel pedersen

42 days came went after a recent parliamentary election in Denmark before a new government was formed on Tuesday evening.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Novo Nordisk / PR/Henning Larsen Architects

    Retention, retention, retention – Danish life science firms shower employees in extra benefits

    For subscribers

  • Photo: Tidsvilde Stine/Ekstra Bladet/Ritzau Scanpix

    Strained Danish job market poses challenge for Novo's newest expansion

    For subscribers

  • Anette Steenberg, CEO, Medicon Valley Alliance. | Photo: Copenhagen Capacity / PR

    Scandinavian life science cluster praises "significant" Novo decision to invest in Denmark

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Arnd Wiegmann/Reuters/Ritzau Scanpix
Pharma & biotech

Novartis beats Kesimpta sales expectations in Q4

Multiple sclerosis treatment Kesimpta, based on Genmab-developed ofatumumab, has generated more than analysts predicted in Q4’22.
  • Janssen's books disappointing sales of Genmab-developed Darzalex
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix
Pharma & biotech

Analyst: Strong Novo Nordisk outlook should satisfy investors

For subscribers

Foto: Jens Dresling/Ritzau Scanpix
Pharma & biotech

Studies of Wegovy in higher-than-approved doses begin

For subscribers

Foto: Novo Nordisk
Pharma & biotech

Rare Disease business comes in slightly below expectations for Novo Nordisk

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk meets upgraded guidance, setting new revenue record

For subscribers

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk doubles obesity sales in 2022

For subscribers

Further reading

Foto: Robert Galbraith/Reuters/Ritzau Scanpix
Pharma & biotech

Amgen takes on Abbvie blockbuster Humira with unusual price plan

Abbvie’s multibillion-dollar generating anti-inflammatory drug, Humira, is about to face competition for the first time, as Amgen launches an almost identical product using an unconventional strategy.

For subscribers

Foto: Leo Pharma / Pr
Pharma & biotech

Spokesperson: Laid-off Leo employees have leg-up in job hunt at Novo and Lundbeck

Dismissed Leo Pharma workers get to skip the line when looking for jobs at Novo Nordisk and Lundbeck via a new job tunnel – and Bavarian Nordic would like to snatch a few people up, too.

For subscribers

Foto: Kim Kyung-Hoon/Reuters/Ritzau Scanpix
Other

Takeda elected 2022's best place to work in Europe

The Best Places to Work organization has compiled a list of 2022’s 17 best European workplaces – the top three are all life science companies.

For subscribers

Latest news

  • Novartis beats Kesimpta sales expectations in Q4 – 11:49
  • Analyst: Strong Novo Nordisk outlook should satisfy investors – 11:09
  • Studies of Wegovy in higher-than-approved doses begin – 10:01
  • Rare Disease business comes in slightly below expectations for Novo Nordisk – 09:48
  • Novo Nordisk meets upgraded guidance, setting new revenue record – 09:20
  • Novo Nordisk doubles obesity sales in 2022 – 08:54
  • Maersk and German start-up wants to enhance emission visibility for global e-trade – 08:27
  • Novo Nordisk predicts wide range for 2023 sales growth – 07:38
  • Pfizer hopes Covid-19 sales will increase in the long run – 31 Jan
  • Amgen takes on Abbvie blockbuster Humira with unusual price plan – 31 Jan
See all

Jobs

  • Application Manager

  • Experienced Patent Counsel

  • Commercial Director

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Jobs

  • Application Manager

  • Experienced Patent Counsel

  • Commercial Director

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Sr. Director, Drug Safety Physician

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Regulatory Affairs Professional

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge